Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Innovation Council · Running

DDG-MRI DDG-MRI for cancer detection - A novel medical imaging approach that correlates to FDG-PET without ionising radiation

Coordinator
Hadassah Medical Organization, Israel
Runs
1 December 2024 to 30 November 2027
Status
Running
EU funding
€3.6m
Total cost
€3.6m
Partners
9 organisations in 7 countries
Type
European Innovation Council
Grant agreement
101185775

What the project is doing

In the project's own words, from its summary on CORDIS.

Positron emission tomography (PET) measurements of 2-deoxy-2-[18F]fluoro-D-glucose (FDG) uptake have been widely used clinically for tumour staging, prognosis, and treatment monitoring, where it can be more sensitive at detecting treatment response than magnetic resonance imaging (MRI) and computerised tomography (CT) -based evaluations of tumour size. 2-deoxy-D-glucose (DG) and FDG are non-metabolisable derivatives of D-glucose that get trapped in the cells of active or malignant tissues.

Even though highly sensitive, the ionising radiation associated with FDG-PET limits its frequent application (typically not more than 2-3 examinations per year) and its use in populations such as children and pregnant women, who may otherwise benefit from this valuable and unique diagnostic imaging examination. As such, alternative techniques are highly demanded. The DDG-MRI project aims at providing the benefits of FDG-PET without ionising radiation.

We propose an MRI-based imaging agent and technique that will provide PET-like images with MRI without ionising radiation. To this end, we will make use of 1) a novel DG analogue that is uniformly labelled with deuterons ([D8]2-deoxy-D-glucose) and 2) rapid and sensitive deuterium MRI schemes targeted at demonstrating the uptake of this agent in malignant tissues further to intravenous administration. The expected spatial resolution will exceed that of FDG-PET (~2-3 mm in plane) in a scan time of about 2 min, with a clinically acceptable and commercially relevant dose of the labelled compound.

DDG-MRI is likely to be quickly adopted by medical centres as it does not require significant hardware changes, does not change the MRI suite workflow, and is expected to cost the same as a PET scan. This consortium comprises six partners (two from industry) from five countries, enthusiastic about making DDG-MRI a medical reality for cancer detection and treatment monitoring.

Who is involved

OrganisationCityCountryRole
Hadassah Medical OrganizationJerusalemIsraelCoordinator
Ge Healthcare GmbHDusseldorfGermanyThird party
Universitaet UlmUlmGermanyParticipant
Aarhus UniversitetAarhus CDenmarkParticipant
Danmarks Tekniske UniversitetKongens LyngbyDenmarkParticipant
CortecnetLes UlisFranceParticipant
Universita Degli Studi Di TorinoTorinoItalyParticipant
Universidade De AveiroAveiroPortugalParticipant
Ge Healthcare LimitedChalfont St GilesUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI